Shows
WTR Healthcare HappeningsTaking Aim at Norovirus; Cocrystal Pharma's (COCP) Clinical Antiviral OpportunityIn this episode of the WTR Healthcare Happenings Podcast, Tim Gerdeman and Robert Sassoon speak with Jim Martin, Co‑CEO and CFO of Cocrystal Pharma (NASDAQ: COCP). Martin explains the company’s Nobel Laureate‑developed drug discovery platform, which uses high-resolution crystallography to target viral regions resistant to mutation, enabling broad‑spectrum antivirals. The discussion highlights Cocrystal’s lead candidate, CDI‑988, a dual‑indication antiviral for coronaviruses and noroviruses, with a particular focus on advancing the norovirus program due to high global unmet need. Martin outlines the ongoing human challenge norovirus study at Emory University, CDI‑988’s potential as therapy and prophy...
2026-02-0427 minWTR Healthcare HappeningsHow Entropy Neurodynamics (ASX: ENP) Is Shaping Psychedelic‑Assisted Therapy: Psilocin Programs, Binge Eating Disorder, and EEG BiomarkerIn this episode of the WTR Healthcare Happenings Podcast, host Tim Gerdeman and healthcare analyst Robert Sassoon are joined by Dr. Jim Gilligan, President and Chief Science Officer of Entropy Neurodynamics (ASX: ENP), formerly Tryptamine Therapeutics. Dr. Gilligan explains the motivation behind the company’s rebrand and its decision to prioritize three core therapeutic targets: Binge Eating Disorder, Fibromyalgia, and Irritable Bowel Syndrome/abdominal pain. Although Entropy has reported positive Phase 2a results using oral psilocybin across these indications, Dr. Gilligan outlines why the company is shifting its strategy toward developing proprietary IV‑delivered psilocin formulations combined with psychotherapy, begi...
2026-01-2828 minWTR Healthcare HappeningsAnixa' (ANIX) T-Cell Innovations Demonstrate Early Breakthrough Potential in Solid TumorsIn this special Flashcast episode of the WTR Healthcare Happenings podcast, Tim Gerdeman sits down with WTR Healthcare analyst Robert Sassoon to discuss his Initiation of Coverage Report on Anixa Biosciences. Their conversation explores Anixa’s two clinical‑stage programs—one, an innovative CAR‑T cell therapy for terminal ovarian cancer patients, and the other, a breast cancer vaccine designed for both treatment and prevention. They review Phase 1 results, upcoming 2026 milestones, and how Anixa differentiates itself through both its scientific platforms and disciplined financial management.
2026-01-2213 minWTR Healthcare HappeningsThe lure of the NASDAQ for BiotechsIn this special Flashcast episode of the WTR Healthcare Happenings podcast, Tim Gerdeman and WTR Healthcare analyst Robert Sassoon break down why more than 90% of biotech companies listed on a U.S. exchange choose NASDAQ over the NYSE.
2026-01-1607 minWTR Healthcare HappeningsRedefining Cancer Treatment: Calidi Biotherapeutics’ Approach to Enable Systemic Oncolytic Virotherapy for Metastatic DiseaseIn this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon speak with Eric Poma PhD, CEO of Calidi Biotherapeutics Inc (NYSE American: CLDI). The discussion focuses on how Calidi is solving the "delivery problem" in cancer treatment, and specifically how to transport cancer-killing oncolytic viruses systemically through the bloodstream without the body’s immune system neutralizing them before they reach the tumor.
2026-01-0818 minWTR Healthcare HappeningsCo-Diagnostic' Technology to Deliver Accessible, High-Fidelity Gold Standard PCR Testing Like No OtherIn this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon speak with Dwight Egan, CEO of Co-Diagnostics Inc. (NASDAQ: CODX), about the company’s evolution from a pandemic-era PCR testing provider to a diversified molecular diagnostics leader. In our discussion, Egan highlights the Co-DX PCR Pro, a portable, cost-effective device that delivers gold-standard PCR testing outside the lab and explains how its patented Co-Primer multiplexing technology sets it apart from competitors. Our conversation also covers Co-Diagnostics’ “razor-and-blade” business model, its pipeline of testing capabilities targeting high-impact infectious diseases...
2025-12-2319 minWTR Healthcare HappeningsCEO Jagi Gill on How Apyron' Innovative Neurostimulation Solution Breaks the Chronic Pain BarrierIn this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon talk with Apyron CEO Jagi Gill about the company's innovative neurostimulation technology for chronic pain, an all too prevalent affliction affecting millions of people. Gill explains why Apyron’s patient-focused approach stands out, and outlines the market opportunity and commercialization strategy.
2025-12-1922 minWTR Healthcare HappeningsRenovoRx’ Differentiated Targeted Drug Delivery Platform Addressing Hypovascular cancersIn this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon speak with Shaun Bagai, CEO of RenovoRx (NASDAQ: RNXT). The company is pioneering targeted oncology therapies and commercializing RenovoCath™, an FDA-cleared multi-specialty local drug delivery device for high unmet needs. We discuss the innovation and advantages of its TAMP™ (Trans-Arterial Micro-Perfusion) platform—powered by the proprietary dual-balloon catheter—and how it sets RenovoRx apart in treating hard-to-reach hypovascular tumors like pancreatic cancer. The conversation also covers RenovoCath’s commercialization strategy and key milestones in its Phase 3 cl...
2025-12-1816 minWTR Healthcare HappeningsVivos Therapeutics’ Mission to Transform Sleep TreatmentIn this WTR Healthcare Happenings Spotlight Flashcast, host Tim Gerdeman sits down with WTR's Healthcare Analyst Robert Sassoon to discuss his recently published initiation of coverage on Vivos Therapeutics (NASDAQ: VVOS). The conversation explores Vivos’ innovative approach to treating obstructive sleep apnea (OSA), the company's transformative shift to a vertically integrated, patient-centric business model, and the significant market opportunity ahead. Tune in for insights on growth strategy, economics of the pivot, and what investors should watch as Vivos reimagines sleep health.
2025-12-1011 minWTR Healthcare HappeningsGenSight Biologics' Novel Gene Therapy Approach to Reversing Blindness from Genetic Eye DisordersOn the latest WTR Healthcare Happenings podcast episode, we welcomed Jan Eryk Umiastowski, CFO of GenSight Biologics (Euronext Paris: SIGHT), a late clinical-stage biopharma company based in Paris, France, primarily focused on developing and commercializing novel disease-modifying gene therapies aimed at reversing vision loss from severe neurodegenerative retinal diseases. He discusses GenSight's development pipeline, what's unique about the company's approach to gene therapy and upcoming target milestones.
2025-12-0311 min
En órbitaEn órbita - Novedades Dance Locales - 22/11/25Nuestras novedades dance más destacadas de las últimas semanas donde encontramos a: PurP! con su nuevo álbum, el debut de Brunetto, lo nuevo de Lopezhouse, Karretero, Castellano & Marien Novi, Oscar Escapa, Kid Cala y Fernando Lagreca junto a Pedro Mercado. PurP! "Doquier"Brunetto "War games 2025"Lopezhouse, Paul Deep ft Lannakise "Deep eyes (extended version)"BizZa, Karretero "Marathon"PurP! "Sexy"Hertz & Oscar Escapa "Habemus"Castellano & Marien Novi "Take"Karretero "For me"PurP! "Main truth"Kid Cala "Noise dealer"L...
2025-11-222h 00WTR Healthcare HappeningsAinos' Director of Corporate Development Jack Lu Discusses the AI Nose Platform' continuing 2025 momentum and Looks Ahead into 2026In our latest WTR Healthcare Happenings podcast, we welcome back Jack Lu, Director of Corporate Development at Ainos (NASDAQ: AIMD) to discuss key takes from the company's recently reported 3Q25 earnings release. He also dives into Ainos’ latest strategic partnerships with Topco and NEXCOM, its expanding IP moat with seven new patents, and outlines the roadmap for 2026—commercial scale-up, industrial deployments and expansion plans beyond Asia.
2025-11-2015 minWTR Healthcare HappeningsThe Psychedelic Investment Environment: A New Era of OptimismHear about the latest dynamic developments in the therapeutic psychedelics sector in our WTR Healthcare Happenings Flashcast. Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer at WTR, and Robert Sassoon, WTR's Senior Healthcare Analyst, discuss the October's fundraising activity surge; what has contributed to renewed investor confidence; comparisons with the hype-driven cycle of 2021; impact on valuations in the sector; and sustainability of the positive trend going into 2026.
2025-11-1410 minWTR Healthcare HappeningsSolvonis Therapeutics: Redefining Treatment for Alcohol Use Disorder Through Capital-Efficient InnovationIn this episode of WTR Healthcare Happenings, Anthony Tennyson, CEO and Co-Founder of Solvonis Therapeutics (LSE: SVNS | OTC: SLVNF), joins host Tim Gerdeman, Vice Chair and Co-Founder of Water Tower Research, and analyst Robert Sassoon.The clinical-stage, UK-listed company (LSE: SVNS) focuses on developing novel medicines for high-burden CNS disorders, with its current focus primarily on Alcohol Use Disorder (AUD). Our discussion delves into Solvonis' lead clinical programs, SVN-001 and SVN-002, that aim to address this major societal problem. Tennyson highlights anticipated upcoming milestones and outlines Solvonis' capital-efficient business m...
2025-11-0722 minWTR Healthcare HappeningsReversing the Irreversible: NurExone Biologic’s (NRXBF) Regenerative Exosome Therapy for Spinal Cord and Nerve InjuriesIn this episode of WTR Healthcare Happenings, Dr. Lior Shaltiel, CEO of NurExone Biologic (TSXV: NRX | OTCQB: NRXBF), and Yoram Drucker, Founder, VP of Business Development, and Active Chairman, join host Tim Gerdeman, Vice Chair and Co-Founder of Water Tower Research, along with WTR Senior Equity Research Analyst Robert Sassoon.The conversation explores NurExone’s groundbreaking exosome-based ExoTherapy platform and its lead candidate ExoPTEN, designed to regenerate damaged neurons following spinal cord and optic nerve injuries—two massive unmet medical markets. Shaltiel and Drucker discuss the company’s remarkable preclinical data showing functional recovery in up to 100% of ani...
2025-10-3016 minWTR Healthcare HappeningsPharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRLIn this episode of WTR Healthcare Happenings, WTR's Tim Gerdeman, and Robert Sassoon welcomes back Nick Kadysh, Founding CEO and President of PharmAla Biotech (OTCQB: MDXXF). The discussion explores the evolving global regulatory environment for psychedelics—particularly MDMA—the ripple effects of the Lykos Therapeutics FDA Complete Response Letter (CRL) disclosures, and PharmAla’s strategic approach to research, manufacturing, and commercialization of clinical-grade MDMA and next-generation analogues.
2025-10-2220 minWTR Healthcare HappeningsCEO Dr. Amit Kumar Discusses Anixa Biosciences' Innovative Approach to Help T-Cells Address Solid TumorsIn this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Amit Kumar, PhD, CEO of Anixa Biosciences (NASDAQ: ANIX) to discuss t-cells and Anixa's two clinical developments, one involving the modification of CAR-T technology to overcome the challenges of treating solid tumors, specifically ovarian cancer, and the other, an innovative breast cancer vaccine that trains antigen-specific t-cells to recognize and attack breast cancer cells, especially those from triple-negative breast cancer, the most aggressive form of breast cancer. Kumar also talks about the company's robust balance sheet and...
2025-10-1524 minWTR Healthcare HappeningsVeru's CEO Mitch Steiner on Enobosarm's value-added to the booming GLP-1 Weight Loss Drug MarketWe welcome back Veru's CEO Mitch Steiner to our latest WTR Healthcare Happenings podcast. In this podcast, Steiner gives us his thoughts on the latest trends in the rapidly evolving GLP-1 market for weight loss, discusses the data from enobosarm's Phase 2b data, and explains Veru's obesity drug development strategy in the wake of its recent positive interactions with the FDA.
2025-10-0821 minWTR Healthcare HappeningsRevolutionizing Stroke Prevention: InspireMD’s CGuard® Prime and the Future of Carotid StentingIn this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Marvin Slosman, CEO of InspireMD (NASDAQ: NSPR), to discuss how the company is transforming carotid artery disease treatment with its groundbreaking CGuard® Prime Carotid Stent System. The conversation covers FDA approval, clinical data, market adoption, competitive positioning, and InspireMD’s long-term growth strategy.
2025-09-2419 minWTR Healthcare HappeningsTransforming Global Healthcare Access: Doc.com’s Mission for Free Basic TelemedicineIn this episode of the WTR Healthcare Happenings Podcast, Water Tower Research’s Tim Gerdeman and Robert Sassoon sit down with Charles Nader, CEO of Doc.com, to discuss the company’s mission to provide free basic telehealth services worldwide. The conversation covers Doc.com’s innovative use of AI and blockchain, strategic partnerships, competitive differentiation, and plans for scaling telemedicine and pharmacy services globally.
2025-09-1824 minWTR Healthcare HappeningsPsychedelics Sector Deals 2025: AbbVie/Gilgamesh Impact and Market OutlookIn this special Flashcast edition of the WTR Small-Cap Spotlight Podcast, host Tim Gerdeman sits down with Robert Sassoon, Senior Research Analyst at Water Tower Research, to discuss the recent wave of deal activity in the psychedelics sector.Robert breaks down major transactions, including why the AbbVie/Gilgamesh deal marks a potential turning point for the industry, and what these developments could mean for sector valuations going forward.Whether you’re an investor tracking emerging growth sectors or just curious about the rapidly evolving psychedelics ma...
2025-09-0306 minWTR Healthcare HappeningsLudwig's Dr. Marvin Hausman on Why Its Cheek-Swabbing mRNA Technology Platform Promises to be a Revolutionary Diagnostic ToolIn this episode of the WTR Healthcare Happenings podcast, we are joined by Ludwig Enterprises (OTC: LUDG) Co-Founder and Chief Scientific Officer Marvin Hausman MD to talk about the company's innovative and proprietary mRNA genomic technology. Dr. Hausman discusses how it revolutionizes early detection of chronic inflammatory-driven diseases like cancer and advances the adoption of personalized medicine.
2025-08-2034 minWTR Healthcare HappeningsCEO Brent Lucas on Why Envoy Medical's Device Technology is Currently the Only Change Agent in Hearing HealthCEO Brent Lucas of Envoy Medical (NASDAQ: COCH), an innovative hearing health technology company and sole US-domiciled cochlear implant company joins the WTR Healthcare Happenings podcast to talk about hearing loss, the third most chronic physical condition prevalent in the US, and how Envoy's innovative device technology can disrupt the hearing solutions market that has long lacked transformative advancements. Lucas discusses Envoy's two fully implantable hearing solution products, one in the market (Esteem), the only FDA approved middle ear implant for moderate to severe hearing loss, and the other (Acclaim), a cochlear implant targeting severe to profound hearing loss whic...
2025-08-1331 minWTR Healthcare HappeningsAinos' Director of Corporate Development Jack Lu on Why SmellTech Platform AI Nose is a Foundational Product in AIIn our latest WTR Healthcare Spotlight podcast, we were joined by Jack Lu, Director of corporate Development at Ainos (NASDAQ: AIMD) to discuss the company's pioneering smell digitization AI technology platform, AI Nose; diversification of the platform's penetration across multiple verticals through strategic partnerships; commercialization opportunities and expansion goals.
2025-07-2223 minWTR Healthcare HappeningsLisata Therapeutics' CEO Dr. David Mazzo and CMO Dr. Kristen Buck On the Promise Of Certepetide for Pancreatic CancerIn this episode of WTR Healthcare Spotlight podcast, we are joined by Lisata Therapeutics' (NASDAQ: LSTA) CEO David Mazzo, PhD and Chief Medical Officer Kristen Buck, MD to talk about, Certepetide, the company's novel solid tumor targeting and penetration technology with tumor microenvironment modifying properties. We also dive into the recently reported positive preliminary results from Lisata's lead program (Ascend), a Phase 2b study investigating Certepetide for metastatic pancreatic ductal adenocarcinoma (the most common and aggressive form of pancreatic cancer), Lisata's partnerships, and upcoming milestones.
2025-07-1823 minWTR Healthcare HappeningsCybin CEO Doug Drysdale On What Distinguishes CYB003 from Other Aspiring Novel Depression TreatmentsIn our first rebranded WTR Healthcare Spotlight, Cybin CEO Doug Drysdale joins Water Tower Research’s Tim Gerdeman and Senior Analyst Robert Sassoon to discuss the company's non-traditional financing strategy as it continues to advance its development pipeline. Drysdale also probes into data that highlight advantages that distinguish Cybin's lead program CYB003 from other aspiring late-stage novel therapies in the depression treatment landscapeCybin (NYSE: CYBN) is a late-stage clinical development company focused on developing novel psychedelic-based neuropsychiatric compounds. Its two lead candidates, targeting two of the most pervasive mental health disorders, are ps...
2025-07-1421 minWTR Healthcare HappeningsA Conversation with PharmAla Biotech CEO Nick Kadysh on What the Trump FDA and AI mean for the Biotech LandscapeIn this episode of the WTR Biotech Spotlight, Water Tower Research’s Tim Gerdeman is joined by Nick Kadysh, Founding CEO and President of Toronto-headquartered Life Sciences company, PharmAla Biotech (CSE: MDMA; OTCQB: MDXXF),and WTR Senior Analyst Robert Sassoon for an insightful discussion on arguably the two main topics that are currently concentrating the minds of biotech industry folk: The implications of the Trump Administration's FDA reforms and AI's role in reshaping the industry.With over a decade of experience as a Public Affairs and Regulatory expert, Nick Kady...
2025-06-2524 minWTR Healthcare HappeningsTrevi Therapeutics CEO Jennifer Good Discusses Oral Haduvio Benefit in Chronic CoughTrevi Therapeutics CEO Jennifer Good joins us on this week’s WTR Biotech Spotlight to talk about the recent and impressive clinical data for Haduvio in IPF-associated chronic cough and refractory chronic cough. We discuss Haduvio’s unique mechanism and unscheduled status, supported by a human abuse study. Listen to learn more about Trevi Therapeutics and how Haduvio could change the chronic cough treatment landscape.
2025-06-1829 minWTR Healthcare HappeningsHow the Biomarker Era Will Transform the CNS Treatment Landscape with Psilera CEO Dr. Chris WitowskiIn this episode of the WTR Biotech Spotlight, Water Tower Research’s Tim Gerdeman is joined by Dr. Chris Witowski, CEO of Psilera, and WTR Senior Analyst Robert Sassoon for an insightful discussion on the company’s pioneering work in neuroplastogen drug development and delivery technologies.Dr. Chris Witowski, CEO and Co-Founder of Psilera, an early-stage biotech company focused on developing next-generation neuroplastegens for neurological and neuropsychiatric disorders, shares his thoughts and insights on the evolution of biomarkers in the neurosciences, the latest developments and trends in CNS-focused biomarkers and t...
2025-06-1214 minWTR Healthcare HappeningsApimeds Pharmaceuticals CEO Erik Emerson Discusses Purified Bee Venom for Knee Osteoarthritis and Other Inflammatory ConditionsOn this week’s WTR Biotech Spotlight, we speak with Apimeds CEO Erik Emerson about the newly NYSE listed company and the development of Apitox, a purified honeybee venom, for knee osteoarthritis and multiple sclerosis. We discuss the therapeutic properties of bee venom and the clinical/regulatory plans to bring Apitox to the US market. Listen to learn more about Apimeds and its novel approach to treat inflammatory pain.
2025-06-1129 minWTR Healthcare HappeningsZomedica's (OTCQB: ZOMDF) CEO Highlights Its Innovative Product Offerings and Significant Growth Opportunities in the Animal Healthcare MarketCEO of Zomedica (OTCQB: ZOMDF) Larry Heaton joins WTR's Tim Gerdeman and Robert Sassoon in this week's WTR Small-Cap Spotlight episode. Since 2021 Zomedica has expanded its suite of innovative offerings from one product to six. All are proprietary, highly differentiated either diagnostic or therapeutic devices, to help veterinarians not only improve the quality of care for pets, but also importantly to help improve the efficiency of how vets themselves operate to maximize the profitability of their practices. Heaton provides a concise overview of Zomedica’s products, explains how they differentiate themselves from what exists in the market today and the...
2025-05-2817 minWTR Healthcare HappeningsEnlivex Therapeutics CEO Oren Hershkovitz, PhD Discusses Allocetra Cell Therapy and Recent Knee Osteoarthritis DataEnlivex Therapeutics CEO Oren Hershkovitz, PhD joins us on this week’s WTR Biotech Spotlight to talk about how the company’s cell therapy, Allocetra, reprograms macrophages to treat inflammatory diseases. We dive into the recent Phase 1 data in knee osteoarthritis and what to expect from the randomized Phase 2 readout later this year, as well as the market opportunity. Listen to learn more about Enlivex Therapeutics and its off-the-shelf cell therapy platform.
2025-05-2127 minWTR Healthcare HappeningsMost-Favored-Nation Drug Pricing Lacks Executive PlanTim Gerdeman and Do Kim discuss President Trump’s executive order on lowering drug prices through Most-Favored-Nation reference pricing. They talk about the goal of the executive order and whether the government has the authority for price-setting in the pharmaceutical industry.
2025-05-1409 minWTR Healthcare HappeningsCurrent State of Biotech, Market Pressure Points, Obesity and PD-1/VEGFTim Gerdeman and Do Kim discuss the current state of biotech, what brought us here, and how the rest of year may look for the group. They also review recent market-shaping events in the obesity space and progress of the Keytruda-busting PD-1/VEGF bispecifics.
2025-05-0818 minWTR Healthcare HappeningsWTR Biotech Flashcast: Neuroscience, Alzheimer’s and Biogen IOCOn this week's episode of WTR Biotech Spotlight, Tim Gerdeman and Robert Sassoon sit down for a quick flashcast to review Robert's last three reports; Neuroscience, Alzheimer’s and Biogen IOC.
2025-04-2416 minWTR Healthcare HappeningsAnnovis Bio's CEO Discusses the promise of Buntanetap in Redefining the Treatment of Alzheimer's and Parkinson's and Next StepsFounding CEO and President of Annovis Bio (NYSE: ANVS) Dr Maria Maccecchini joins WTR's Tim Gerdeman and Robert Sassoon in this week's WTR Biotech Spotlight episode. Annovis is a late clinical-stage drug platform company developing novel disease-modifying therapies for neurodegenerative diseases, to include targeting Alzheimer's and Parkinson's, as well as other related diseases. Dr Maccecchini discusses the company's lead drug candidate Buntanetap and its promise as a treatment that can go beyond simply slowing the rate of cognitive decline in Alzheimer's and Parkinson's patients.
2025-03-1918 minWTR Healthcare HappeningsVeru, Inc. CEO Mitch Steiner Discusses Recent Enobosarm Data and Preserving Muscle While on GLP-1 Obesity DrugsCEO Mitch Steiner joins us on this week’s WTR Biotech Spotlight to talk about the next generation of drugs focusing on lean mass (muscle) preservation for obesity patients on the popular GLP-1 therapies. He reviews the recent enobosarm Phase 2b data and highlights the importance of functional clinical benefit in addition to maintaining lean mass. Listen to learn more about Veru and its obesity drug enobosarm
2025-02-2634 minWTR Healthcare HappeningsOS Therapies CEO Paul Romness and CBO Gerald Commisiong Discuss Recent OST-HER2 Phase 2b Data and Next StepsCEO Paul Romness and CBO Gerald Commisiong of OS Therapies join us on our WTR Biotech Spotlight podcast to talk about the OST-HER2 Phase 2b data in recurrent, liver metastatic osteosarcoma and what it could mean for patients with this aggressive cancer. We discuss the plan to approach the FDA and their confidence in a potential accelerated filing. Listen to learn more about OS Therapies and its cancer immunotherapy.
2025-02-1225 minWTR Healthcare HappeningsLaunch of WTR Biotech Spotlight Podcast with Tim Gerdeman and Do KimWe are launching a WTR Spotlight podcast focused on biotech companies and industry. Listen to Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer of Water Tower Research, and Do Kim, Senior Research Analyst, discuss what to expect and who will be joining us in future episodes.
2025-02-0306 min